Immix Biopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $524.20M
- P/E (TTM)
- –
- Dividend yield
- –
About Immix Biopharma
Pharmaceutical Preparations, SIC 2834
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops chimeric antigen receptor cell therapies to treat light chain amyloidosis and other serious medical conditions. Its research focuses on utilizing its proprietary cell therapy platform to create therapeutic candidates. The company's lead product candidate is NXC-201, an investigational cell therapy designed for individuals suffering from relapsed or refractory light chain amyloidosis. Immix Biopharma operates in the biopharmaceutical industry and directs its therapeutic programs toward patient populations diagnosed with these critical disorders.
The company conducts its clinical and operational activities across the United States and internationally. It maintains a wholly-owned research and development subsidiary located in Australia. Clinical trials evaluating its lead cell therapy candidate take place at study sites within the United States as well as international locations. Immix Biopharma is incorporated in Delaware and maintains its corporate headquarters in Los Angeles, California.
Summary of the business section of Immix Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Immix Biopharma, Inc.
- Headquarters
- Los Angeles, CA
- Address
- 11400 West Olympic Blvd., Suite 200 90064
- Phone
- (888) 958-1084
- Website
- immixbio.com
- Employees
- 21, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Crowe LLP, Los Angeles, California
Stock & identifiers
- Ticker
- IMMX
- Exchange
- Nasdaq
- IPO date
- Dec 17, 2021
- Shares outstanding
- 72M, Aug 3, 2026
- Public float
- $35.71M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1873835
- CUSIP
- 45258H106
- ISIN
- US45258H1068
- EIN
- 45-4869378
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ilya M. Rachman | CEO and Chairman, Director | 1,141,683 |
| Gabriel S. Morris | CFO, President, Director | 718,273 |
| Jane Buchan | Director | 28,705 |
| Helen C. Adams | Director | 181,004 |
| Magda Marquet | Director | 72,342 |
| Jason Hsu | Director | 4,815,163 |
| Nancy T. Chang | Director | 925,130 |
| Carey Ng | Director | 1,051,471 |
| Yekaterina Chudnovsky | Director | 3,247,326 |
Employees
Headcount reported in annual reports
“of March 20, 2026, we had 21 employees, all of which are full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 22, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 17, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 13, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |